Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: is neoangiogenesis occurring?

被引：15

作者：

Burt, RK ^{[1
]}

Oyama, Y ^{[1
]}

Traynor, A ^{[1
]}

Quigley, K ^{[1
]}

Brush, M ^{[1
]}

Rodriguez, J ^{[1
]}

Barr, WG ^{[1
]}

机构：

[1] Northwestern Univ, Med Ctr, Div Immunotherapy, Dept Med, Chicago, IL 60611 USA

来源：

BONE MARROW TRANSPLANTATION | 2003年 / 32卷 / Suppl 1期

关键词：

scleroderma; hematopoietic stem cell transplantation;

D O I：

10.1038/sj.bmt.1704055

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Systemic sclerosis (SSc) is presumed to be an immune-mediated vasculopathy of unknown etiology. SSc is unresponsive to most immune-modulating therapies except for intravenous cyclophosphamide, which is reported to demonstrate some benefit. We, therefore, dose-escalated cyclophosphamide to 200 mg/kg and added rabbit ATG 7.5 mg/kg along with infusion of unselected hematopoietic stem cells to minimize the cytopenic interval. Engraftment occurred rapidly (day 8) with minimal unexpected toxicity, no infections, and unexpectedly rapid improvement in the modified Rodnan Skin Score.

引用

页码：S65 / S67

页数：3

共 17 条

[1] Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis [J].

Artlett, CM ;

Smith, JB ;

Jimenez, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (17) :1186-1191

[2]

Bachleitner-Hofmann T, 2002, CLIN EXP RHEUMATOL, V20, P85

[3] Phase I/II trial of autologous stem cell transplantation in systemic sclerosis:: procedure related mortality and impact on skin disease [J].

Binks, M ;

Passweg, JR ;

Furst, D ;

McSweeney, P ;

Sullivan, K ;

Besenthal, C ;

Finke, J ;

Peter, HH ;

van Laar, J ;

Breedveld, FC ;

Fibbe, VE ;

Farge, D ;

Gluckman, E ;

Locatelli, F ;

Martini, A ;

van den Hoogen, F ;

van de Putte, L ;

Schattenberg, AVN ;

Arnold, R ;

Bacon, PA ;

Emery, P ;

Espigado, I ;

Hertenstein, B ;

Hiepe, F ;

Kashyap, A ;

Kötter, I ;

Marmont, A ;

Martinez, A ;

Pascual, MJ ;

Gratwohl, A ;

Prentice, HG ;

Black, C ;

Tyndall, A .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :577-584

[4]

*CAN ASS RAD ONC, 1998, CAN MED ASSOC J S, V158, pS35

[5]

CLEMENTS PJ, 1993, J RHEUMATOL, V20, P1892

[6] The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology [J].

Coghlan, JG ;

Mukerjee, D .

CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (06) :495-499

[7]

Harvey Georgina R., 1999, Current Opinion in Rheumatology, V11, P495, DOI 10.1097/00002281-199911000-00010

[8] Vascular function in systemic sclerosis [J].

Herrick, AL .

CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (06) :527-533

[9]

Inaba S, 2002, LANCET, V360, P2083, DOI 10.1016/S0140-6736(02)11976-3

[10] High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes [J].

McSweeney, PA ;

Nash, RA ;

Sullivan, KM ;

Storek, J ;

Crofford, LJ ;

Dansey, R ;

Mayes, MD ;

McDonagh, K ;

Nelson, JL ;

Gooley, TA ;

Holmberg, LA ;

Chen, CS ;

Wener, MH ;

Ryan, K ;

Sunderhaus, J ;

Russell, K ;

Rambharose, J ;

Storb, R ;

Furst, DE .

BLOOD, 2002, 100 (05) :1602-1610

← 1 2 →